Research and development for neglected diseases: More is still needed, and faster

The Lancet Global Health

Volumn 1, Issue 6, 2013, Pages

  Utzinger, Jürg ^a,b   Keiser, Jennifer ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; TRIBENDIMIDINE; UNCLASSIFIED DRUG; DRUG; VACCINE;

CHEMOTHERAPY; CLINICAL RESEARCH; DEATH; DIARRHEA; HELMINTHIASIS; HUMAN; LETTER; MALARIA; NEGLECTED DISEASE; PRIORITY JOURNAL; RISK; TUBERCULOSIS; DYSENTERY; NEGLECTED DISEASES;

DYSENTERY; HUMANS; MALARIA; NEGLECTED DISEASES; PHARMACEUTICAL PREPARATIONS; TUBERCULOSIS; VACCINES;

EID: 84888327259     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(13)70148-7     Document Type: Letter

References (17)

1. Hotez PJ, Fenwick A, Savioli L, Molyneux DH Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009, 373:1570-1575.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
3. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
4. May RM Parasites, people and policy: infectious diseases and the Millennium Development Goals. Trends Ecol Evol 2007, 22:497-503.
5. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation 2012, WHO, WHO, Geneva.
6. Alonso PL, Tanner M Public health challenges and prospects for malaria control and elimination. Nat Med 2013, 19:150-155.
7. Pedrique B, Strub-Wourgaft N, Some C, et al. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. Lancet Global Health 2013, published October 24. http://dx.doi.org/10.1016/S2214-109X(13)70078-0.
8. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002, 359:2188-2194.
9. Keiser J, Utzinger J The drugs we have and the drugs we need against major helminth infections. Adv Parasitol 2010, 73:197-230.
10. Utzinger J, N'Goran EK, Caffrey CR, Keiser J From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop 2011, 120(suppl 1):S121-S137.
11. Nwaka S, Ridley RG Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2003, 2:919-928.
12. Croft SL Public-private partnership: from there to here. Trans R Soc Trop Med Hyg 2005, 99(suppl 1):S9-14.
13. Moran M A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2005, 2:e302.
14. Xiao SH, Wu HM, Tanner M, Utzinger J, Wang C Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China. Acta Trop 2005, 94:1-14.
15. Xiao SH, Utzinger J, Tanner M, Keiser J, Xue J Advances with the Chinese anthelminthic drug tribendimidine in clinical trials and laboratory investigations. Acta Trop 2013, 126:115-126.
16. Soukhathammavong P, Odermatt P, Sayasone S, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial. Lancet Infect Dis 2011, 11:110-118.
17. Qian MB, Yap P, Yang YC, et al. Efficacy and safety of tribendimidine against Clonorchis sinensis. Clin Infect Dis 2013, 56:e76-e82.